Stathopoulos G P, Malamos N A, Aravantinos G, Rigatos S, Christodoulou Ch, Stathopoulos J, Skarlos D
First Department of Oncology, Errikos Dunant Hospital, Semitelou 2A, 115 28, Athens, Greece.
Cancer Chemother Pharmacol. 2007 Jun;60(1):123-8. doi: 10.1007/s00280-006-0383-6. Epub 2006 Nov 17.
To investigate the weekly administration of topotecan combined with paclitaxel in pretreated advanced ovarian cancer patients; our objectives were to determine efficacy, toxicity and survival.
The chemotherapy agents, topotecan and paclitaxel were administered on a weekly basis for 3 consecutive weeks, every 28 days. The plan was to give three courses (each course included three once-weekly infusions). The dose of topotecan was 1.75 mg/m(2) and of paclitaxel 70 mg/m(2).
From January 2004 until January 2006, 45 patients were enrolled in this multicenter trial; 44 patients were evaluable for response and toxicity. The median age was 60 years old (range 39-82 years) and performance status was 0-2. Thirty-nine patients were in stage III and 5 in stage IV. All patients had been pretreated with carboplatin or cisplatin in combination with paclitaxel. Complete and partial responses were seen in 39% of the patients, stable disease in 43% and progressive disease in 18%; median survival time was 9 months, range 2-24+ months, (95% CI: 7.9-10.2). There was a notable absence of grade 3 toxicity except for neutropenia in 11% of the patients.
The combination of topotecan and paclitaxel administered on a weekly basis is a well-tolerated chemotherapy schedule. The response rate of 39% is quite high for patients with pretreated ovarian cancer.
研究拓扑替康联合紫杉醇每周给药方案用于经治晚期卵巢癌患者的疗效；我们的目标是确定疗效、毒性和生存期。
化疗药物拓扑替康和紫杉醇每28天连续3周每周给药一次。计划给予三个疗程（每个疗程包括三次每周一次的输注）。拓扑替康剂量为1.75mg/m²，紫杉醇剂量为70mg/m²。
从2004年1月至2006年1月，45例患者纳入该多中心试验；44例患者可评估疗效和毒性。中位年龄为60岁（范围39 - 82岁），体能状态为0 - 2。39例患者为Ⅲ期，5例为Ⅳ期。所有患者均接受过卡铂或顺铂联合紫杉醇的预处理。39%的患者出现完全缓解和部分缓解，43%为疾病稳定，18%为疾病进展；中位生存时间为9个月，范围2 - 24 +个月，（95%CI：7.9 - 10.2）。除11%的患者出现中性粒细胞减少外，显著缺乏3级毒性。
拓扑替康和紫杉醇每周联合给药是一种耐受性良好的化疗方案。对于经治卵巢癌患者，39%的缓解率相当高。
